IOTA gains a regulated foothold in the US as BitGo support opens institutional access. BitGo integration strengthens exchange liquidity, custody options and overall readiness for broader American market participation. IOTA announced a partnership with BitGo, a regulated digital asset custodian in the United States. BitGo will begin supporting the IOTA Mainnet in the first week [...]]]>IOTA gains a regulated foothold in the US as BitGo support opens institutional access. BitGo integration strengthens exchange liquidity, custody options and overall readiness for broader American market participation. IOTA announced a partnership with BitGo, a regulated digital asset custodian in the United States. BitGo will begin supporting the IOTA Mainnet in the first week [...]]]>

IOTA Expands Into U.S. Market With New BitGo Custody Partnership

  • IOTA gains a regulated foothold in the US as BitGo support opens institutional access.
  • BitGo integration strengthens exchange liquidity, custody options and overall readiness for broader American market participation.

IOTA announced a partnership with BitGo, a regulated digital asset custodian in the United States. BitGo will begin supporting the IOTA Mainnet in the first week of December. This addition brings the network token under a custody platform used by over 4,900 institutions and exchanges worldwide.

BitGo has been in the digital asset infrastructure business since 2013 and is regulated by the South Dakota Division of Banking. The firm holds an insurance policy of up to $250 million that covers theft, mishandling of keys, or loss. With this structure in place, its inclusion allows US institutions to handle, store, buy, and sell IOTA under a fully regulated framework.

BitGo’s custody platform already supports more than 1,500 digital tokens. Its structure includes wallet services, trading, lending, and settlement tools, which give institutions broad flexibility. This move grants the network new exposure across institutional markets in the United States.

IOTA Gains Support Across BitGo Services

The partnership gives IOTA access to BitGo’s backend infrastructure, which already supports many exchanges. This allows exchanges to offer IOTA trading without building a new system. Market makers also gain more flexibility through trading options supported by custody services.

BitGo’s over-the-counter desk, which carries out trades through voice and chat, provides another channel for access.The service has previously been used by institutions acquiring assets like Ethereum. By offering IOTA in this manner, large-volume participants can stay within a regulated structure while executing trades.

Under United States regulations, this arrangement provides clarity to those interested in using IOTA for financial purposes. Institutions, exchanges, and users who operate under regulatory or tax obligations now have an approved path for accessing and managing IOTA.

IOTA described this development as,

IOTA Prepares for 2026 Network Shift

Its partnership with BitGo aside, CNF reported that the network is preparing to launch TWIN and TLIP on its mainnet in the first quarter of 2026. This upgrade is expected to bring strong growth in network activity, supported by AfCFTA trade flows.

On December 3, the project also announced a partnership with LayerZero and Stargate. This allows it to connect with more than 150 blockchain networks, including Ethereum, Solana, Base and BNB Smart Chain. This multi-chain support expands its global reach and its trading use cases.

Following the BitGo announcement, IOTA’s token value recorded a small lift, trading at $0.1024 with a nearly 1% gain in the past 24 hours.

]]>
Market Opportunity
MIOTAC Logo
MIOTAC Price(IOTA)
$0.06906
$0.06906$0.06906
-1.52%
USD
MIOTAC (IOTA) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

The first-ever ETFs for XRP and Dogecoin are expected to launch in the US tomorrow. Here's what you need to know. Continue Reading: And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow
Share
Coinstats2025/09/18 04:33
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

        Highlights:  Inflows of altcoins in exchanges have surged by 22% in early 2026. An increase in deposits indicates a growing sell-side pressure. The 
Share
Coinstats2026/02/22 02:03